Skip to main content
Fachgebiete
Automobil + Motoren Bauwesen + Immobilien Business IT + Informatik Elektrotechnik + Elektronik Energie + Nachhaltigkeit Finance + Banking Management + Führung Marketing + Vertrieb Maschinenbau + Werkstoffe Versicherung + Risiko
DE
EN
Themenseiten
Organisationspsychologie Projektmanagement Marketing Smart Manufacturing
Bücher
Zeitschriften
Weitere Formate
Podcasts Webinare Technik Webinare Wirtschaft Kongresse Veranstaltungskalender Awards
Jetzt Einzelzugang starten
Zugang für Unternehmen
Referenzkunden
MTZ-Fachkongress

Antriebe und Energiesysteme von morgen


Austausch von Automobil- und Energiewirtschaft

Am 14./15. Mai geht es in Chemnitz um die Mobilitätswende durch Elektro- und Wasserstofffahrzeuge.
Erweiterte Suche
Anmelden
nach oben
Biomass Conversion and Biorefinery
Erschienen in: Biomass Conversion and Biorefinery 4/2024

12.03.2022 | Review Article

Effect of immobilization, mutation, and microbial stresses on increasing production efficiency of “Cyclosporin A”

verfasst von: Fereshteh Falah, Alireza Vasiee, Mohammad Ramezani, Farideh Tabatabaee-Yazdi, Seyed Ali Mortazavi, Abolghasem Danesh

Erschienen in: Biomass Conversion and Biorefinery | Ausgabe 4/2024

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config
loading …

Abstract

Cyclosporin A (CyA) is a secondary metabolite mainly produced by Tolypocladium inflatum. CyA is a non-polar cyclic polypeptide that is widely used in medicine. Its importance is due to its immunosuppressive role making it useful for the treatment of autoimmune diseases, although to some extent, it showed anti-fungal and anti-parasitic properties. In this review, we discuss the biosynthetic pathway, fermentative production (increasing production efficiency by cells, appropriate, and new fermentation process), downstream processing (efficient extraction and purification), and pharmacological activities of CyA.
Vorheriger Artikel Natural antimicrobial and antioxidant compounds for active food packaging applications
Nächster Artikel Bioprospecting lignin biomass into environmentally friendly polymers—Applied perspective to reconcile sustainable circular bioeconomy

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 390 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Maschinenbau + Werkstoffe




 

Jetzt Wissensvorsprung sichern!

Jetzt informieren
Literatur
1.
2.
Demain AL (2000) Small bugs, big business: the economic power of the microbe. Biotechnol Adv 18:499–514CrossRef
3.
Reino JL, Guerrero RF, Hernandez-Galan R, Collado IG (2008) Secondary metabolites from species of the biocontrol agent Trichoderma. Phytochem Rev 7:89–123CrossRef
4.
Ghanbari T, Seid Mohammadkhani H, Babaeizad V (2014) Identification of some secondary metabolites produced by four Penicillium species. Mycologia Iranica 1:107–113
5.
Dreyfuss M, Härri E, Hea H, Kobel H, Pache W, Tscherter H (1976) Cyclosporin a and C. Eur J App Microbiol Biotechnol 3:125–33CrossRef
6.
Sallam LA, El-Refai A-MH, Hamdi A-HA, El-Minofi HA, Abd-Elsalam IS (2005) Studies on the application of immobilization technique for the production of cyclosporin A by a local strain of Aspergillus terreus. J General App Microbiol 51:143–9CrossRef
7.
Anjum T, Azam A, Irum W (2012) Production of cyclosporine A by submerged fermentation from a local isolate of Penicillium fellutanum. Indian J Pharm Sci 74:372CrossRef
8.
Stoppacher N, Kluger B, Zeilinger S, Krska R, Schuhmacher R (2010) Identification and profiling of volatile metabolites of the biocontrol fungus Trichoderma atroviride by HS-SPME-GC-MS. J Microbiol Methods 81:187–193CrossRef
9.
Polizzi V, Adams A, Picco AM, Adriaens E, Lenoir J, Van Peteghem C et al (2011) Influence of environmental conditions on production of volatiles by Trichoderma atroviride in relation with the sick building syndrome. Build Environ 46:945–954CrossRef
10.
Korpi A, Järnberg J, Pasanen A-L (2009) Microbial volatile organic compounds. Crit Rev Toxicol 39:139–193CrossRef
11.
Diamanti AP, Rosado M, Germano V, Scarsella M, Giorda E, Podestà E et al (2011) Reversion of resistance to immunosuppressive agents in three patients with psoriatic arthritis by cyclosporine A: Modulation of P-glycoprotein function. Clin Immunol 138:9–13CrossRef
12.
13.
Survase SA, Kagliwal LD, Annapure US, Singhal RS (2011) Cyclosporin A—a review on fermentative production, downstream processing and pharmacological applications. Biotechnol Adv 29:418–435CrossRef
14.
Tanseer S, Anjum T (2011) Modification of c and n sources for enhanced production of cyclosporin’a’by Aspergillus Terreus. Braz J Microbiol 42:1374–1383CrossRef
15.
Abdel-Fattah Y, Enshasy HE, Anwar M, Omar H, Abolmagd E (2007) Application of factorial experimental designs for optimization of cyclosporin A production by Tolypocladium inflatum in submerged culture. J Microbiol Biotechnol 17:1930–1936
16.
Balaraman K, Mathew N (2006) Optimization of media composition for the production of cyclosporin A by Tolypocladium species. Indian J Med Res 123:525
17.
Agathos S, Marshall J, Moraiti C, Parekh R, Madhosingh C (1986) Physiological and genetic factors for process development of cyclosporine fermentations. J Ind Microbiol 1:39–48CrossRef
18.
Nisha A, Meignanalakshmi S, Ramasamy K (2008) Comparative effect of amino acids in the production of cyclosporine A by solid and submerged fermentations. Biotechnology 7:205–208CrossRef
19.
Berton P, Mishra MK, Choudhary H, Myerson AS, Rogers RD (2019) Solubility studies of cyclosporine using ionic liquids. ACS Omega 4:7938–7943CrossRef
20.
Amarouche N, Boudesocque L, Sayagh C, Giraud M, McGarrity J, Butte A et al (2013) Purification of a modified cyclosporine A by co-current centrifugal partition chromatography: process development and intensification. J Chromatogr A 1311:72–78CrossRef
21.
Survase SA, Bacigalupi C, Annapure US, Singhal RS (2009) Use of coconut coir fibers as an inert solid support for production of cyclosporin A. Biotechnol Bioprocess Eng 14:769–774CrossRef
22.
Robinson T, Singh D, Nigam P (2001) Solid-state fermentation: a promising microbial technology for secondary metabolite production. Appl Microbiol Biotechnol 55:284–289CrossRef
23.
Liddicoat AM, Lavelle EC (2019) Modulation of innate immunity by cyclosporine A. Biochem Pharmacol 163:472–480CrossRef
24.
Borel JF, Feurer C, Magnee C, Stähelin H (1977) Effects of the new anti-lymphocytic peptide cyclosporin A in animals. Immunology 32:1017
25.
Řeháček Z, De-xiu Z (1991) The biochemistry of cyclosporin formation: a review. Process Biochem 26:157–166CrossRef
26.
Wenger R (1985) Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production. U.S. Patent No. 4,554,351
27.
Price DA, Eng H, Farley KA, Goetz GH, Huang Y, Jiao Z et al (2017) Comparative pharmacokinetic profile of cyclosporine (CsA) with a decapeptide and a linear analogue. Org Biomol Chem 15:2501–2506CrossRef
28.
Fliri HG, Wenger RM (2019) Cyclosporine: synthetic studies, structure-activity relationships, biosynthesis and mode of action. De Gruyter, Biochemistry of Peptide Antibiotics, pp 245–288
29.
Spitzfaden C, Braun W, Wider G, Widmer H, Wüthrich K (1994) Determination of the NMR solution structure of the cyclophilin A-cyclosporin A complex. J Biomol NMR 4:463–482CrossRef
30.
Mikol V, Kallen J, Pflügl G, Walkinshaw MD (1993) X-ray structure of a monomeric cyclophilin A-cyclosporin A crystal complex at 2·1 Å resolution. J Mol Biol 234:1119–1130CrossRef
31.
Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G et al (1994) Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 330:1841–1845CrossRef
32.
Rosenthaler J, Keller HP (1990) Comment on cyclosporine assay techniques: an attempt for recommendations. 22(3):1160–1165
33.
Ismailos G, Reppas C, Dressman JB, Macheras P (1991) Unusual solubility behaviour of cyclosporin A in aqueous media. J Pharm Pharmacol 43:287–289CrossRef
34.
Hasumi H, Nishikawa T, Ohtani H (1994) Effect of temperature on molecular structure of cyclosporin A. Biochem Mol Biol Int 34:505–511
35.
Czogalla A (2009) Oral cyclosporine A-the current picture of its liposomal and other delivery systems. Cell Mol Biol Lett 14:139–152CrossRef
36.
Penkler LJ, Müller RH, Runge SA, Ravelli V, inventors; Pharmatec International SRL, assignee (2003) Pharmaceutical cyclosporin formulation with improved biopharmaceutical properties, improved physical quality and greater stability, and method for producing said formulation. United States patent US 6,551,619
37.
Lawen A, Zocher R (1990) Cyclosporin synthetase The most complex peptide synthesizing multienzyme polypeptide so far described. J Biol Chem 265:11355–60CrossRef
38.
Lawen A, Traber R (1993) Substrate specificities of cyclosporin synthetase and peptolide SDZ 214–103 synthetase Comparison of the substrate specificities of the related multifunctional polypeptides. J Biol Chem 268:20452–65CrossRef
39.
Weber G, Leitner E (1994) Disruption of the cyclosporin synthetase gene of Tolypocladium niveum. Curr Genet 26:461–467CrossRef
40.
Kürnsteiner H, Zinner M, Kück U (2002) Immunosuppressants. Springer, Industrial Applications, pp 129–155
41.
Velkov T, Lawen A (2003) Non-ribosomal peptide synthetases as technological platforms for the synthesis of highly modified peptide bioeffectors—cyclosporin synthetase as a complex example. Biotechnol Annu Rev 9:151–197CrossRef
42.
Yang X, Feng P, Yin Y, Bushley K, Spatafora JW, Wang C (2018) Cyclosporine biosynthesis in Tolypocladium inflatum benefits fungal adaptation to the environment. MBio 9:e01211-e1218CrossRef
43.
Velkov T, Horne J, Scanlon MJ, Capuano B, Yuriev E, Lawen A (2011) Characterization of the N-methyltransferase activities of the multifunctional polypeptide cyclosporin synthetase. Chem Biol 18:464–475CrossRef
44.
Bushley KE, Raja R, Jaiswal P, Cumbie JS, Nonogaki M, Boyd AE et al (2013) The genome of Tolypocladium inflatum: evolution, organization and expression of the cyclosporin biosynthetic gene cluster. PLoS genetics 9:e1003496CrossRef
45.
Di Salvo ML, Florio R, Paiardini A, Vivoli M, D’Aguanno S, Contestabile R (2013) Alanine racemase from Tolypocladium inflatum: a key PLP-dependent enzyme in cyclosporin biosynthesis and a model of catalytic promiscuity. Arch Biochem Biophys 529:55–65CrossRef
46.
Hoppert M, Gentzsch C, Schörgendorfer K (2001) Structure and localization of cyclosporin synthetase, the key enzyme of cyclosporin biosynthesis in Tolypocladium inflatum. Arch Microbiol 176:285–293CrossRef
47.
Lazarova T, Weng Z (2003) Cyclosporin A analogues: recent advances. Expert Opinion on Therapeutic Patents 13(9):1327–32
48.
Traber R, Hofmann H, Kobel H (1989) Cyclosporins-new analogues by precursor directed biosynthesis. J Antibiot 42:591–597CrossRef
49.
Loor F, Tiberghien F, Wenandy T, Didier A, Traber R (2002) Cyclosporins: structure− activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC transporter. J Med Chem 45:4598–4612CrossRef
50.
Mutter M, Wenger R, Guichou JF, Keller M, Ruckle T, Woehr T, inventors; Debiopharm SA, assignee (2004) Cyclosporin derivatives and method for the production of said derivatives. United States patent US 6,790,935 
51.
Liu Y, Ruan H, Li Y, Sun G, Liu X, He W et al (2020) Potent and specific inhibition of NTCP-mediated HBV/HDV infection and substrate transporting by a novel, oral-available cyclosporine A analogue. J Med Chem 64:543–565CrossRef
52.
Irum W, Anjum T (2012) Production enhancement of Cyclosporin ‘A’by Aspergillus terreus through mutation. Afr J Biotech 11:1736–1743
53.
Wagner H, Kreher B, Jurcic K (1988) In vitro stimulation of human granulocytes and lymphocytes by pico-and femtogram quantities of cytostatic agents. Arzneimittelforschung 38:273–275
54.
 Wagner H, Kreher B, Arzneimittel-forschung JK (1988) In vitro stimulation of human granulocytes and lymphocytes by pico- and femtogram quantities of cytostatic agents. 38(2):273–275
55.
Zheng Z-W, Li J, Chen H, He J-L, Chen Q-W, Zhang J-H et al (2020) Evaluation of in vitro antileishmanial efficacy of cyclosporin A and its non-immunosuppressive derivative, dihydrocyclosporin A. Parasit Vectors 13:1–14CrossRef
56.
Dawson J, Hurtenbach U, MacKenzie A (1996) Cyclosporin A inhibits the in vivo production of interleukin-1β and tumour necrosis factor α, but not interleukin-6, by a T-cell-independent mechanism. Cytokine 8:882–888CrossRef
57.
Saitoh O, Matsuse R, Sugi K, Nakagawa K, Uchida K, Maemura K et al (1997) Cyclosporine A inhibits interleukin-8 production in a human colon epithelial cell line (HT-29). J Gastroenterol 32:605–610CrossRef
58.
Kitahara K, Kawai S (2007) Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis. Curr Opin Rheumatol 19:238–245CrossRef
59.
Amor KT, Ryan C, Menter A (2010) The use of cyclosporine in dermatology: part I. J Am Acad Dermatol 63:925–946CrossRef
60.
Lee J (2013) Cyclophilin A as a new therapeutic target for hepatitis C virus-induced hepatocellular carcinoma. Korean JPhys Pharmacol 17:375–383CrossRef
61.
Franke EK, Luban J (1996) Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag–cyclophilin A interaction. Virology 222:279–282CrossRef
62.
Rao SN (2006) Treatment of herpes simplex virus stromal keratitis unresponsive to topical prednisolone 1% with topical cyclosporine 0.05%. Am J Ophthalmol 141:771–2CrossRef
63.
64.
Lee J (2010) Use of antioxidants to prevent cyclosporine a toxicity. Toxicol Res 26:163–170CrossRef
65.
Dogra S, Mahajan R, Narang T, Handa S (2017) Systemic cyclosporine treatment in severe childhood psoriasis: a retrospective chart review. J Dermatol Treat 28:18–20CrossRef
66.
Lai VWY, Chen G, Sinclair R (2021) Impact of cyclosporin treatment on health-related quality of life of patients with alopecia areata. J Dermatol Treat 32:250–257CrossRef
67.
St.John J, Ratushny V, Liu KJ, Bach DQ, Badri O, Gracey LE et al (2017) Successful use of cyclosporin A for Stevens-Johnson syndrome and toxic epidermal necrolysis in three children. Pediatric Dermatol 34:540–6CrossRef
68.
Nebbioso M, Alisi L, Giovannetti F, Armentano M, Lambiase A (2019) Eye drop emulsion containing 01% cyclosporin (1 mg/mL) for the treatment of severe vernal keratoconjunctivitis: an evidence-based review and place in therapy. Clin Ophthalmol (Auckland, NZ) 13:1147CrossRef
69.
Shimura S, Watashi K, Fukano K, Peel M, Sluder A, Kawai F et al (2017) Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity. J Hepatol 66:685–692CrossRef
70.
El Enshasy H, Fattah YA, Atta A, Anwar M, Omar H, Magd S et al (2008) Kinetics of cell growth and cyclosporin A production by Tolypocladium inflatum when scaling up from shake flask to bioreactor. J Microbiol Biotechnol 18:128–134
71.
Hodge KT, Krasnoff SB, Humber RA (1996) Tolypocladium inflatum is the anamorph of Cordyceps subsessilis. Mycologia 88:715–719CrossRef
72.
Nakajima H, Hamasaki T, Nishimura K, Kondo T, Kimura Y, Udagawa S-i et al (1988) Isolation of 2-acetylamino-3-hydroxy-4-methyloct-6-enoic acid, a derivative of the “C9-amino acid” residue of cyclosporins, produced by the fungus Neocosmospora vasinfecta EF Smith. Agric Biol Chem 52:1621–3
73.
Sallam LA, El-Refai A-MH, Hamdy A-HA, El-Minofi HA (2003) Abdel-Salam IS. Role of some fermentation parameters on cyclosporin A production by a new isolate of Aspergillus terreus. J General App Microbiol 49:321–8CrossRef
74.
Sawai K, Okuno T, Terada Y, Harada Y, Sawamura K, Sasaki H et al (1981) Isolation and properties of two antifungal substances from Fusarium solani. Agric Biol Chem 45:1223–1228
75.
Moussaïf M, Jacques P, Schaarwächter P, Budzikiewicz H, Thonart P (1997) Cyclosporin C is the main antifungal compound produced by Acremonium luzulae. Appl Environ Microbiol 63:1739–1743CrossRef
76.
Azam A, Anjum T, Irum W (2012) Trichoderma harzianum: a new fungal source for the production of cyclosporin. Bangladesh J Pharmacol 7:33–35CrossRef
77.
Ismaiel AA, El-Sayed E-SA, Mahmoud AA (2010) Some optimal culture conditions for production of cyclosporin a by Fusarium roseum. Brazil J Microbiol 41:1112–23CrossRef
78.
Survase SA, Annapure US, Singhal RS (2009) Statistical optimization of cyclosporin A production on a semi-synthetic medium using Tolypocladium inflatum MTCC 557. Global J Biotechnol Biochem 4:184–192
79.
Zocher R, Madry N, Peeters H, Kleinkauf H (1984) Biosynthesis of cyclosporin A. Phytochemistry 23:549–551CrossRef
80.
Lee M-J, Lee H-N, Han K-B, Kim E-S (2008) Spore inoculum optimization to maximize cyclosporin a production in Tolypocladium niveum. J Microbiol Biotechnol 18:913–917
81.
Lee J, Agathos S (1989) Effect of amino acids on the production of cyclosporin A by Tolypocladium inflatum. Biotech Lett 11:77–82CrossRef
82.
Margaritis A, Chahal PS (1989) Development of a fructose based medium for biosynthesis of cyclosporin-A by Beauveria nivea. Biotech Lett 11:765–768CrossRef
83.
Isaac C, Jones A, Pickard M (1990) Production of cyclosporins by Tolypocladium niveum strains. Antimicrob Agents Chemother 34:121–127CrossRef
84.
Kannan N, Kalaichelvan P (2007) Production of immunosuppressant drug cyclosporin A from Tolypocladium inflatum in presence of L-valine. Allelopath J 19:549–553
85.
Dong H, Jiang J, Yan T, Zhao J (2011) Optimization of cyclosporin A production by Beauveria nivea in continuous fed-batch fermentation. Archives of Biological Sciences 63:907–914CrossRef
86.
Thomas L, Larroche C, Pandey A (2013) Current developments in solid-state fermentation. Biochem Eng J 81:146–161CrossRef
87.
El-Sayed E, Ahmed A, Al-Hagar O (2020) Agro-industrial wastes for production of paclitaxel by irradiated Aspergillus fumigatus under solid-state fermentation. J Appl Microbiol 128:1427–1439CrossRef
88.
Rigo E, Ninow JL, Di Luccio M, Oliveira JV, Polloni AE, Remonatto D et al (2010) Lipase production by solid fermentation of soybean meal with different supplements. LWT-Food Science and Technology 43:1132–1137CrossRef
89.
Sekar C, Balaraman K (1998) Optimization studies on the production of cyclosporin A by solid state fermentation. Bioprocess Eng 18:293–296CrossRef
90.
Murthy MR, Mohan E, Sadhukhan A (1999) Cyclosporin-A production by Tolypocladium inflatum using solid state fermentation. Process Biochem 34:269–280CrossRef
91.
Sharmila K, Thillaimaharani K, Logesh A, Sathishkumar A, Kalaiselvam M (2012) Production of cyclosporin A by saprophytic filamentous fungus Fusarium oxysporum. Int J Pharm Pharm Sci 4:149–153
92.
Pandey A, Soccol CR, Mitchell D (2000) New developments in solid state fermentation: I-bioprocesses and products. Process Biochem 35:1153–1169CrossRef
93.
Ansari SA, Husain Q (2012) Potential applications of enzymes immobilized on/in nano materials: a review. Biotechnol Adv 30:512–523CrossRef
94.
Żur J, Wojcieszyńska D, Guzik U (2016) Metabolic responses of bacterial cells to immobilization. Molecules 21:958CrossRef
95.
Datta S, Christena LR, Rajaram YRS (2013) Enzyme immobilization: an overview on techniques and support materials. 3 Biotech 3:1–9CrossRef
96.
El-Sayed E-SR, Ahmed AS, Hassan IA, Ismaiel AA, Karam El-Din A-ZA (2019) Strain improvement and immobilization technique for enhanced production of the anticancer drug paclitaxel by Aspergillus fumigatus and Alternaria tenuissima. App Microbiol Biotechnol 103:8923–35CrossRef
97.
Ismaiel A, Ahmed A, El-Sayed E (2015) Immobilization technique for enhanced production of the immunosuppressant mycophenolic acid by ultraviolet and gamma-irradiated P enicillium roqueforti. J Appl Microbiol 119:112–126CrossRef
98.
El-Sayed E-SR, Ahmed AS, Hassan IA, Ismaiel AA, Karam El-Din A-ZA (2020) Semi-continuous production of the anticancer drug taxol by Aspergillus fumigatus and Alternaria tenuissima immobilized in calcium alginate beads. Bioprocess and Biosystems Engineering 43:997–1008CrossRef
99.
Foster B, Coutts R, Pasutto F, Dossetor J (1983) Production of cyclosporin A by carrageenan-immobilized Tolypocladium inflatum in an airlift reactor with external loop. Biotech Lett 5:693–696CrossRef
100.
Chun G-T, Agathos S (1989) Immobilization of Tolypocladium inflatum spores into porous celite beads for cyclosporine production. J Biotechnol 9:237–254CrossRef
101.
Survase SA, Annapure US, Singhal RS (2010) Gellan gum as immobilization matrix for production of cyclosporin A. J Microbiol Biotechnol 20:1086–1091CrossRef
102.
Şeker Ş, Beyenal H, Ayhan F, Tanyolaç A (1998) Production of microbial rennin from Mucor miehei in a continuously fed fermenter. Enzyme Microb Technol 23:469–474CrossRef
103.
El-Sayed E, Ahmed A, Abdelhakim H (2020) A novel source of the cardiac glycoside digoxin from the endophytic fungus Epicoccum nigrum: isolation, characterization, production enhancement by gamma irradiation mutagenesis and anticancer activity evaluation. J Appl Microbiol 128:747–762CrossRef
104.
El-Sayed E-SR, Zaki AG, Ahmed AS, Ismaiel AA (2020) Production of the anticancer drug taxol by the endophytic fungus Epicoccum nigrum TXB502: enhanced production by gamma irradiation mutagenesis and immobilization technique. App Microbiol Biotechnol 104:6991–7003CrossRef
105.
Ikehata H, Ono T (2011) The mechanisms of UV mutagenesis. J Radiat Res 52:115–125CrossRef
106.
Faisal RM (2013) The application of the mutagen nitrous acid to improve the free living nitrogen fixation ability of Azotobacter spp. Rafidain J Sci 24:44–54CrossRef
107.
Kim JW, Lee KM, Choi BT, Lee JM, Sung NK, Min KB, inventors; Chong Kun Dang Corp, assignee (1999) Process for manufacturing cyclosporin a by highly productive fusant strain. United States patent US 5,856,141
108.
Domratcheva A, Zhgun A, Novak N, Dzhavakhiya V (2018) The influence of chemical mutagenesis on the properties of the cyclosporine a high-producer strain Tolypocladium inflatum VKM F-3630D. Appl Biochem Microbiol 54:53–57CrossRef
109.
Cirigliano AM, Cabrera GM (2014) Differentiation of cyclosporin A from isocyclosporin A by liquid chromatography/electrospray ionization mass spectrometry with post-column addition of divalent metal salt. Rapid Commun Mass Spectrom 28:465–470CrossRef
110.
Pagans E, Font X, Sánchez A (2006) Emission of volatile organic compounds from composting of different solid wastes: abatement by biofiltration. J Hazard Mater 131:179–186CrossRef
111.
Tarus PK, Lang’at-Thoruwa CC, Wanyonyi AW, Chhabra SC (2003) Bioactive metabolites from trichoderma harzianum and trichoderma longibrachiatum. Bull Chem Soc Ethiop 17(2):185–190
112.
Jeleń H (2003) Use of solid phase microextraction (SPME) for profiling fungal volatile metabolites. Lett Appl Microbiol 36:263–267CrossRef
113.
Balaraman K, Mathew N, inventors; National Research Development Corp UK, assignee (1997) Process for the preparation of cyclosporin a from tolypocladium species. United States patent US 5,656,459
114.
Lam KB, Le Blanc JY, Campbell JL (2020) Separating isomers, conformers, and analogues of cyclosporin using differential mobility spectroscopy, mass spectrometry, and hydrogen–deuterium exchange. Anal Chem 92:11053–11061CrossRef
115.
Hyung S-J, Feng X, Che Y, Stroh JG, Shapiro M (2014) Detection of conformation types of cyclosporin retaining intramolecular hydrogen bonds by mass spectrometry. Anal Bioanal Chem 406:5785–5794CrossRef
116.
Johnas S, Dittrich B, Meents A, Messerschmidt M, Weckert E (2009) Charge-density study on cyclosporine A. Acta Crystallogr D Biol Crystallogr 65:284–293CrossRef
117.
Alvarez AJ, Singh A, Myerson AS (2011) Crystallization of cyclosporine in a multistage continuous MSMPR crystallizer. Cryst Growth Des 11:4392–4400CrossRef
118.
Wong SY, Tatusko AP, Trout BL, Myerson AS (2012) Development of continuous crystallization processes using a single-stage mixed-suspension, mixed-product removal crystallizer with recycle. Cryst Growth Des 12:5701–5707CrossRef
Metadaten
Titel
Effect of immobilization, mutation, and microbial stresses on increasing production efficiency of “Cyclosporin A”
verfasst von
Fereshteh Falah
Alireza Vasiee
Mohammad Ramezani
Farideh Tabatabaee-Yazdi
Seyed Ali Mortazavi
Abolghasem Danesh
Publikationsdatum
12.03.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
Biomass Conversion and Biorefinery / Ausgabe 4/2024
Print ISSN: 2190-6815
Elektronische ISSN: 2190-6823
DOI
https://doi.org/10.1007/s13399-022-02533-x

Weitere Artikel der Ausgabe 4/2024

Biomass Conversion and Biorefinery 4/2024 Zur Ausgabe

Original Article

An investigation on implementing wet torrefaction to dewatered poultry sludge

Original Article

Titanium oxide–coated coconut husk–derived biochar composite and its application for removal of crystal violet dye

Original Article

Synthesis and characterization of ferric@nanocellulose/nanohydroxyapatite bio-composite based on sea scallop shells and cotton stalks: adsorption of Safranin-O dye

Original Article

Oil flax straw processing and utilization

Original Article

Preparation of a garlic peel waste-derived carbon solid acid catalyst with the porous structure for biodiesel production

Original Article

Mechanical, thermal and morphological analysis of hybrid natural and glass fiber-reinforced hybrid resin nanocomposites